Wedbush Issues Optimistic Outlook for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities researchers at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a report issued on Thursday, May 15th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.57) for the quarter, up from their previous forecast of ($0.66). Wedbush currently has a "Neutral" rating and a $4.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals' Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.19) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.42) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at ($0.17) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67).

Other equities analysts also recently issued reports about the company. UBS Group dropped their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Trading Down 5.5%

NASDAQ:ZNTL traded down $0.07 during trading hours on Monday, reaching $1.21. The company had a trading volume of 747,105 shares, compared to its average volume of 1,548,941. The firm has a market cap of $87.06 million, a price-to-earnings ratio of -0.49 and a beta of 1.81. The firm's 50 day moving average price is $1.41 and its 200-day moving average price is $2.30. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $13.00.

Insider Activity at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers purchased 21,000 shares of Zentalis Pharmaceuticals stock in a transaction on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the transaction, the director now directly owns 281,192 shares in the company, valued at $393,668.80. This represents a 8.07% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Barclays PLC raised its stake in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company's stock worth $277,000 after acquiring an additional 11,748 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Zentalis Pharmaceuticals by 22.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock worth $1,507,000 after purchasing an additional 91,152 shares during the period. Virtu Financial LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $76,000. SG Americas Securities LLC raised its position in shares of Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company's stock valued at $171,000 after purchasing an additional 30,240 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Zentalis Pharmaceuticals by 169.2% during the 4th quarter. Russell Investments Group Ltd. now owns 60,021 shares of the company's stock valued at $182,000 after buying an additional 37,726 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.